. 2021 Apr 12;12:642420. doi: 10.3389/fimmu.2021.642420

Table 3.

Statistical values for flow cytometry data analysis.

Dataset	Main effect		Interactions		Multiple comparisons
Dataset	F (DFn,DFd)	p-value	F (DFn,DFd)	p-value	Effect	Groups	p-value
Flow cytometry data analysis for T-cells from popliteal and inguinal lymph nodes
CD4⁺ males	Treatment: F (1, 10) = 3.139	0.1069	F (1, 10) = 0.3061	0.5922	N/A
CD4⁺ males	Genotype: F (1, 10) = 0.6463	0.4401	F (1, 10) = 0.3061	0.5922	N/A
CD4⁺CCR7⁺ males	Treatment: F (1, 10) = 0.1196	0.7367	F (1, 10) = 0.1991	0.6650	Treatment	Vehicle	0.0814
	Treatment: F (1, 10) = 0.1196	0.7367			Treatment	Paclitaxel	0.2116
	Genotype: F (1, 10) = 11.86	0.0063			Genotype	WT	0.9514
	Genotype: F (1, 10) = 11.86	0.0063			Genotype	eIF4E^S209A	0.9998
CD4⁺CD44^±CD25^± males	Cell populations: F (2, 30) = 809.1	<0.0001	F (6, 30) = 0.2916	0.9362	No genotype or treatment difference within CD4⁺CD44⁺CD25^-, CD4⁺CD44^-CD25⁺, or CD4⁺CD44⁺CD25⁺ populations.
CD4⁺CD44^±CD25^± males	Genotype-treatment: F (3, 30) = 0.6686	0.5780	F (6, 30) = 0.2916	0.9362
CD4⁺ females	Treatment: F (1, 10) = 17.44	0.0019	F (1, 10) = 3.920	0.0759	Treatment	Vehicle	0.3920
	Treatment: F (1, 10) = 17.44	0.0019			Treatment	Paclitaxel	0.6742
	Genotype: F (1, 10) = 0.1340	0.7219			Genotype	WT	0.0101
	Genotype: F (1, 10) = 0.1340	0.7219			Genotype	eIF4E^S209A	0.3831
CD4⁺CCR7⁺ females	Treatment: F (1, 10) = 0.0027	0.9591	F (1, 10) = 0.0341	0.8571	Treatment	Vehicle	0.3583
	Treatment: F (1, 10) = 0.0027	0.9591			Treatment	Paclitaxel	0.2532
	Genotype: F (1, 10) = 6.933	0.0250			Genotype	WT	0.9985
	Genotype: F (1, 10) = 6.933	0.0250			Genotype	eIF4E^S209A	0.9996
CD4⁺CD44^±CD25^± females	Cell populations: F (2, 30) = 1893	<0.0001	F (6, 30) = 2.406	0.0512	CD4⁺CD44⁺CD25^- Genotype ns
	Genotype-treatment: F (3, 30) = 2.452	0.0827			CD4⁺CD44⁺CD25^- Treatment	Vehicle	0.0011
	Genotype-treatment: F (3, 30) = 2.452	0.0827			CD4⁺CD44⁺CD25^- Treatment	Paclitaxel	0.7767
CD8⁺ males	Treatment: F (1, 10) = 3.180	0.1049	F (1, 10) = 0.5157	0.4891	N/A
CD8⁺ males	Genotype: F (1, 10) = 0.6004	0.4564	F (1, 10) = 0.5157	0.4891	N/A
CD8⁺CCR7⁺ males	Treatment: F (1, 10) = 0.0917	0.7681	F (1, 10) = 0.1555	0.7016	Treatment	Vehicle	0.0433
	Treatment: F (1, 10) = 0.0917	0.7681			Treatment	Paclitaxel	0.1044
	Genotype: F (1, 10) = 16.48	0.0023			Genotype	WT	>0.9999
	Genotype: F (1, 10) = 16.48	0.0023			Genotype	eIF4E^S209A	0.9491
CD8⁺CD44^±CD25^± males	Cell populations: F (2, 30) = 772.5	<0.0001	F (6, 30) = 1.591	0.1842	CD8⁺CD44⁺CD25^- Genotype ns
	Genotype-treatment: F (3, 30) = 1.096	0.3660			CD8⁺CD44⁺CD25^-Treatment	Vehicle	0.1579
	Genotype-treatment: F (3, 30) = 1.096	0.3660			CD8⁺CD44⁺CD25^-Treatment	Paclitaxel	0.0396
CD8⁺ females	Treatment: F (1, 10) = 5.496	0.0410	F (1, 10) = 3.684	0.0839	Treatment	Vehicle	0.6174
	Treatment: F (1, 10) = 5.496	0.0410			Treatment	Paclitaxel	0.4863
	Genotype: F (1, 10) = 0.0273	0.8720			Genotype	WT	0.0730
	Genotype: F (1, 10) = 0.0273	0.8720			Genotype	eIF4E^S209A	0.9875
CD8⁺CCR7^± females	Treatment: F (1, 10) = 0.1574	0.6999	F (1, 10) = 0.0371	0.8510	Treatment	Vehicle	0.1422
	Treatment: F (1, 10) = 0.1574	0.6999			Treatment	Paclitaxel	0.2125
	Genotype: F (1, 10) = 10.15	0.0097			Genotype	WT	0.9991
	Genotype: F (1, 10) = 10.15	0.0097			Genotype	eIF4E^S209A	0.9681
CD8⁺CD44^±CD25^± females	Cell populations: F (2, 30) = 788.2	<0.0001	F (6, 30) = 0.7166	0.6392	No genotype or treatment difference within CD8⁺CD44⁺CD25^-, CD8⁺CD44^-CD25⁺, or CD8⁺CD44⁺CD25⁺ populations.
CD8⁺CD44^±CD25^± females	Genotype-treatment: F (3, 30) = 0.5383	0.6597	F (6, 30) = 0.7166	0.6392
Flow cytometry data analysis for myeloid cells from DRG
Males CD11b⁺CD45⁺CD40^±MHCII^±	Cell populations: F (2, 24) = 84.59	<0.0001	F (6, 24) = 1.803	0.1410	CD40⁺MHCII⁺ Treatment ns
	Genotype-treatment: F (3, 24) = 1.139	0.3535			CD40⁺MHCII⁺ Genotype	WT	0.4651
	Genotype-treatment: F (3, 24) = 1.139	0.3535			CD40⁺MHCII⁺ Genotype	eIF4E^S209A	0.0275
Females CD11b⁺CD45⁺CD40^±MHCII^±	Cell populations: F (2, 24) = 141.3	<0.0001	F (6, 24) = 4.720	0.0026	CD40⁺MHCII⁺ Treatment	Vehicle	0.0140
	Cell populations: F (2, 24) = 141.3	<0.0001			CD40⁺MHCII⁺ Treatment	Paclitaxel	0.0055
	Genotype-treatment: F (3, 24) = 5.042	0.0075			CD40⁺MHCII⁺ Genotype	WT	0.5182
	Genotype-treatment: F (3, 24) = 5.042	0.0075			CD40⁺MHCII⁺ Genotype	eIF4E^S209A	<0.0001

Two-way ANOVA was performed followed by Tukey’s post-hoc for multiple comparisons between genotypes and treatments for each sex. p ≤ 0.05 was considered significant (bolded).